Kura Oncology Inc (KURA)
Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.
KURA SEC Filing Email Alerts Service
Company Name: |
Kura Oncology Inc |
Website: |
www.kuraoncology.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding KURA: |
23 |
Total Market Value Held by ETFs: |
$196.76M |
Total Market Capitalization: |
$1.55B |
% of Market Cap. Held by ETFs: |
12.65% |
|
|
March 29, 2024 6:51 AM Eastern
Strong Buy (3.86 out of 4)
74th percentile
|
|